A Randomized Open-Label Phase 2 Trial Of Sipuleucel-T With Concurrent Versus Sequential Administration Of Abiraterone Acetate Plus Prednisone In Men With Metastatic Castrate Resistant Prostate Cancer
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
This study will look at the manufacture of sipuleucel-T, the safety of study treatments, how the immune system responds to the study treatments, and if prostate specific antigen (PSA) values change over time.
Description
This study will look at the manufacture of sipuleucel-T, the safety of study treatments, how the immune system responds to the study treatments, and if prostate specific antigen (PSA) values change over time.
Details
| Condition | Prostate Cancer |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX3785 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.